Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Denak is a Japanese chemical company specializing in the production of monochloroacetic acid (MCA) and its derivatives, such as sodium monochloroacetate (SMCA). Established in 1971 as a joint venture between Denka Company Limited and Nouryon, the company is a leading global supplier of high-purity chemical intermediates. Its products are essential for the synthesis of various pharmaceuticals, including ibuprofen, diclofenac, and synthetic vitamins, as well as agrochemicals and surfactants. Denak operates a major production facility at the Omi Plant in Niigata, Japan, utilizing advanced synthesis technologies to meet international quality standards. The company plays a vital role in the global pharmaceutical supply chain by providing reliable, high-quality raw materials for active pharmaceutical ingredient (API) manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Denak.